International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 13 Issue 1, January - March, Pages:83-89

Molecular Characterization of Carbapenem Resistant Gram?Negative Bacilli in a Tertiary Care Cancer Centre

Parthiban Rudrapathy, Shythya K, Sajani Samuel, Sarath KE, Saravanan Murugesan

Infections are common in patients living with cancer, and they depend upon proper and effective antibiotics to both prevent and treat bacterial infections. Carbapenems are the drug of choice for the treatment of many multidrug resistant (MDR) hospital acquired infections. Resistance to carbapenems is also not uncommon and is increasingly being reported nowadays. The aim of this study was todetermine the prevalence of carbapenem resistant gram negative bacteria and its encoding genes from cancer patients at a tertiary care cancer centre in North Kerala, India. A total of 350 clinical samples were processed and analyzed during the study period. Among the samples processed GNB was the predominant (n = 140), followed by Gram-positive bacteria (n = 133) and fungi (n = 9). Much of the bacterial growth was observed in the age group 61-70.  Urine samples were the predominant followed by blood. The most common isolate was Escherichia coli followed by Klebsiella pneumoniae.K. pneumoniae was highly resistant to all of the antibiotic groups when compared to E. coli. When compared to P. aeruginosaA. baumannii showed high levels of resistance. Carbapenem resistance was found in 46 (32.8%) of the isolates. NDM-1 was the most predominant gene. Amikacin and colistin were found to be the most effective antibiotics tested. This study provides important data regarding prevalence of carbapenem resistance GNB and most importantly the current prevalence of NDM -1 and OXA-48, and the rising trend of NDM -1 in our tertiary care cancer centre.

Keywords: Carbapenem resistant, Gram-negative bacteria, Molecular Characterization, Cancer patients, Metallo-?-Lactamase, Antibiotic resistant.
Full HTML:


  1. Safdar A, Bodey G, Armstrong D. Infections in patients with cancer: overview. PrincPract Cancer Infect Dis. 2011:3-15. doi: 10.1007/978-1-60761-644-3_1.
  2. Veeraraghavan B, Jesudason MR, Prakasah JAJ, Anandan S, Sahni RD, Pragasam AK, Bakthavatchalam YD, Selvakumar RJ, Dhole TN, Rodrigues C, Roy I, Joshi S, Chaudhuri BN, Chitnis DS. Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report. Indian J Med Microbiol. 2018;36(1):32-6. doi: 10.4103/ijmm.IJMM_17_415, PMID 29735823.
  3. Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The ”old” and the ”new” antibiotics for MDR gram-negative pathogens: for whom, when, and how. Front Public Health. 2019;7:151. doi: 10.3389/fpubh.2019.00151, PMID 31245348.
  4. Manohar P, Leptihn S, Lopes BS, Nachimuthu R. Dissemination of carbapenem resistance and plasmids encoding carbapenemases in Gram-negative bacteria isolated in India. JAC Antimicrob Resist. 2021;3(1):dlab015. doi: 10.1093/jacamr/dlab015, PMID 34223092.
  5. Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013;80(4):225-33. doi: 10.3949/ccjm.80a.12182, PMID 23547093.
  6. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7);Suppl 7:S565-75. doi: 10.1093/cid/ciz830, PMID 31724043.
  7. Patel G, Bonomo RA. ’Stormy waters ahead’: global emergence of carbapenemases. Front Microbiol. 2013;4:48. doi: 10.3389/fmicb.2013.00048, PMID 23504089.
  8. Chakraborty T, Shaw R, Chatterjee DS, Datta DL, Sengupta DA. Review on recent advancement of therapeutic interventions in combating multidrug resistant bacteria. Int J Life Sci Pharm Res. 2020;10(5):166-79. doi: 10.22376/ijpbs/ijlpr.2020.
  9. Al-Zahrani IA. Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. A review of current challenge. Saudi Med J. 2018;39(9):861-72. doi: 10.15537/smj.2018.9.22840, PMID 30251728.
  10. CLSI. Performance standards for antimicrobial susceptibility testing; twenty-ninth informational supplement. Wayne, PA: CLSI; 2019.
  11. Murugesan S, Perumal N, Mahalingam SP, Dilliappan SK, Krishnan P. Analysis of antibiotic resistance genes and its associated SCCmec types among nasal carriage of methicillin resistant coagulase negative staphylococci from community settings, Chennai, Southern India. J ClinDiagn Res. 2015;9(8):DC01-5. doi: 10.7860/JCDR/2015/11733.6307, PMID 26435940.
  12. Okoche D, Asiimwe BB, Katabazi FA, Kato L, Najjuka CF. Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLOS ONE. 2015;10(8):e0135745. doi: 10.1371/journal.pone.0135745, PMID 26284519.
  13. Workneh M, Yee R, Simner PJ. Phenotypic methods for detection of carbapenemase production in carbapenem-resistant organisms: what method should your laboratory choose? ClinMicrobiolNewsl. 2019;41(2):11-22. doi: 10.1016/j.clinmicnews.2019.01.001.
  14. Justus DL. Multidrug resistant Gram negative bacterial isolates from Intensive Care Unit in a tertiary Care Centre in Kerala with special reference to molecular detection of BLA NDM1 gene. JMSCR. 2020;08(12):177-85. doi: 10.18535/jmscr/v8i12.30.
  15. Rudrapathy P, Athira KV, Samuel S, Murugesan S. Phenotypic Detection of Metallo-Beta-Lactamase (MBL) Producing Gram-Negative Bacteria and Their Prevalence in a Tertiary Care Cancer Centre..(2021). Int J Pharm Sci.;12(3):56-62. DOI:10.22376/ijpbs.2021.12.3.B56-B62.
  16. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. MicrobiolSpectr. 2016 Apr;4(2):10.1128/microbiolspec.VMBF-0016-2015. doi: 10.1128/microbiolspec.
  17. Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed research international. 2016 Oct;2016.
  18. Shalini Maya A, Prabhakar K, Lakshmi SY. A Study on prevalence and evaluation of clinical isolates from community acquired infections using different media in semiurban areas. World J Med Sci. 2010;5(2):49-53.
  19. Oberoi L, Singh N, Sharma P, Aggarwal A. ESBL, MBL and Ampcβ Lactamases Producing Superbugs - Havoc in the Intensive Care Units of Punjab India. J ClinDiagn Res. 2013;7(1):70-3. doi: 10.7860/JCDR/2012/5016.2673, PMID 23450498.
  20. Anago E, Ayi-Fanou L, Akpovi CD, Hounkpe WB, Agassounon-DjikpoTchibozo M, Bankole HS, Sanni A. Antibiotic resistance and genotype of beta-lactamase producing Escherichia coli in nosocomial infections in Cotonou, Benin. Ann ClinMicrobiolAntimicrob. 2015;14:5. doi: 10.1186/s12941-014-0061-1, PMID 25595314.
  21. Chacko A, Jacob AM, Pulicken M, Mathew P, Paul J. Clinico-microbiological profile of sepsis with carbapenem-resistant Gram-negative isolates among patients presenting to a large tertiary care hospital in South Kerala. J AcadClinMicrobiol. 2020;22(2):76-81. doi: 10.4103/jacm.jacm_30_21.
  22. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. ClinMicrobiol Rev. 2005;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005, PMID 16223952.
  23. World Health Organization. Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization; 2014.
  24. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263-72. doi: 10.1016/j.molmed.2012.03.003, PMID 22480775.
  25. Webster DP, Gaulton T, Woodford N, Pike R, Turton J, Perry C, Bowler IC. Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiellapneumoniae strain during meropenem therapy. Int J Antimicrob Agents. 2010;36(6):575-6. doi: 10.1016/j.ijantimicag.2010.08.003, PMID 20869852.
  26. Shaebani A, Ghanadian A. Ali Gm. The prevalence of check Ndm-1 gene causing beta-lactam antibiotic resistance in Klebsiellapneumoniae isolates from clinical samples and plasmid curing. 2016;6(4):1-6.


[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions